Screen Readers Skip to Content
Tweet Facebook Buffer

New Vaccines for Head and Neck Cancer Therapy

Author: Edward P. Cohen, MD : Contact: www.immcellther.net

Published: 2015-11-30

Synopsis and Key Points:

The vaccine is designed to induce an immune response against cancer cells that remain in patients who have completed conventional therapy.

Main Digest

ICT has developed a new vaccine for patients with head and neck cancer. The vaccine is designed to induce a powerful immune response against cancer cells that remain in patients who have completed conventional therapy. The vaccine is designed as an adjunct, not a replacement, to conventional cancer treatments.

Head and neck cancer defined as a cancer that starts in the lip, mouth, nasal cavity, paranasal sinuses, pharynx, larynx or parotid glands. Head and neck cancers can also begin in the salivary glands, but salivary gland cancers are relatively uncommon. The symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice.

A Phase I/II clinical trial based on ICT's technology for 37 patients with head and neck cancer has been approved by FDA for further development. The vaccine will be prepared under contract at the University of Pittsburgh Cancer Institute where the trial will be carried out.

The vaccine is prepared by transfer of DNA from the patient's own tumor into an FDA-approved, highly immunogenic foreign to the patient (allogeneic) cell line where antigens characteristic of the patient's cancer are expressed. The vaccine is naturally taken-up by dendritic (antigen presenting) cells that present tumor-antigens to cytotoxic ("killer") T lymphocytes in the patient. The activated "killer" lymphocytes then seek out and destroy residual cancer cells, the common source of recurrent disease.

This type of vaccine has multiple advantages:

ICT's core technology was developed at the University of Illinois College of Medicine under the leadership of Edward P. Cohen, MD, and a highly recognized tumor immunologist.

Numerous preclinical studies published in leading scientific journals indicate that immunization with ICT's vaccines induces strong therapeutic immune responses in mice with cancer.

Four patents that protect the company's technology have been issued in the United States and Europe. One additional patent, entitled, "Cancer Vaccines and Therapeutic Methods," that protects the Company's strategy for the identification of tumor antigens, was recently issued.

ICT's technologies were developed with funds from the NIH, the American Cancer Society, the Komen Foundation, the Department of Defense, the Illinois Department of Public Health, and from private capital.

Learn more by visiting www.immcellther.net

Related Documents


Important:

Disabled World uses cookies to help provide and enhance our services to you and tailor some content and advertising. By continuing you agree to the Disabled World Cookie Policy, Privacy Policy and Terms of Service.

Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World.

Please report outdated or inaccurate information to us.